http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kentaro Ohuchi,Naohisa Miyakoshi,Yuji Kasukawa,Toyohito Segawa,Hayato Kinoshita,Chie Sato,Masashi Fujii,Yoichi Shimada 대한골다공증학회 2019 Osteoporosis and Sarcopenia Vol.5 No.4
Objectives: The purpose of this study is to evaluate the effects of teriparatide (TPTD) on bone mineral density (BMD), bone strength, and bone quality in Akita mouse models of diabetes mellitus. Methods: Twelve-week-old female Akita mice and control mice (C57/BL/6NCrSlc) were divided into 4 groups: control mice treated with vehicle (n ¼ 7) or TPTD (n ¼ 6); and Akita mice treated with vehicle (n ¼ 6) or TPTD (n ¼ 7). TPTD or vehicle was administered subcutaneously 3 times a week for 8 weeks. Blood glucose, serum sclerostin, total tibial BMD, femoral shaft bone strength, and bone quality using Fourier-transform infrared spectroscopy imaging were evaluated. Results: No significant differences in serum sclerostin levels were evident among these groups after 8 weeks of treatment. TPTD significantly increased BMD in control mice (þ12.7%, P ¼ 0.02) and Akita mice (þ29.2%, P ¼ 0.001) compared with vehicle. Maximum load and stiffness were significantly higher in Akita mice treated with TPTD than in Akita mice treated with vehicle (þ56.6%, P ¼ 0.03 and þ 90.5%, P ¼ 0.02, respectively). On Fourier-transform infrared spectroscopy imaging, the mineral/matrix ratio was significantly lower in Akita mice treated with vehicle than in control mice (12.2%, P ¼ 0.02), and TPTD treatment significantly increased the mineral/matrix ratio (P ¼ 0.003). Conclusions: TPTD thus improved BMD and bone strength in both control mice and Akita mice, with improvements in the mineral/matrix ratio among Akita mice.
Kentaro Ohuchi,Naohisa Miyakoshi,Yuji Kasukawa,Toyohito Segawa,Hayato Kinoshita,Yoichi Shimada 대한골다공증학회 2015 Osteoporosis and Sarcopenia Vol.1 No.2
Objectives: Diabetes mellitus (DM) causes secondary osteoporosis, which reduces bone mineral density (BMD) and bone strength. Akita mice (AM) are DM model mice used to evaluate glucose metabolism. However, bone metabolism in AM remains unclear. The purpose of this study was to evaluate BMD, bone strength, and serum sclerostin levels in AM. Methods: Female AM and control mice (C57/BL/6NCrSlc; CM) were divided into four groups: (1) a CM group sacrificed at 14 (CM-14w; n ¼ 8) or (2) 18 weeks of age (CM-18w; n ¼ 6); and (3) an AM group sacrificed at 14 (AM-14w; n ¼ 9) or (4) 18 weeks of age (AM-18w; n ¼ 6). Blood glucose level, serum sclerostin level, total tibial BMD, and femoral shaft bone strength were evaluated at each time point. Results: Blood glucose levels were significantly higher in AM than in CM (p < 0.001). Serum sclerostin levels were significantly lower in AM- 18w than in CM-18w (p < 0.001). BMD was significantly lower in AM-14w than in CM-14w (p ¼ 0.004). Stiffness of the femoral shaft was significantly lower in AM-18w than in CM-14w (p ¼ 0.04). Body weight (r ¼ 0.608, p < 0.01) and maximum load (r ¼ 0.438, p < 0.05) were significantly positively correlated with serum sclerostin levels, while blood glucose levels showed a significant negative correlation (r¼?0.708, p < 0.01). Conclusions: AM showed decreased BMD and bone strength with lower levels of serum sclerostin than CM. © 2015 The Korean Society of Osteoporosis. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).